Toll Free Helpline (India): 1800 1234 070

Rest of World: +91-9810852116

Free Publication Certificate

Vol. 12, Issue 1 (2023)

Development of recombinant partial nucleoprotein of rabies virus as the potential antigen for developing in house immunodiagnostics

Author(s):
Hridya Susan Varughese, Chethana Chandrahasa, Kavitha GM, Akhila DS, Shreya Gopinath, Kavitha Govindaiah, Tilak Chandan, Vinay C Prakash Rao, Madhusudhan Hosamani, Sharada Ramakrishnaiah, Rathnamma Doddamane, Divakar Hemadri and Shrikrishna Isloor
Abstract:
Rabies viral nucleoprotein is proven to be antigenic and immunogenic in nature. Monoclonal antibody binding characterises the Rabies viral nucleoprotein's immune-reactivity. However, studies on reactivity of nucleoproteins to polyclonal antibodies are limited. In this study, a partial Rabies viral nucleoprotein gene of 516 bp was cloned into a pET-32a (+) vector, and prokaryotic expression was induced to obtain a protein of 24.1 kDa. The protein obtained was further characterised by Western blot and indirect ELISA. Our research discovered Rabies nucleoprotein immune-reactivity in polyclonal sera and suspected that the epitopes' are conformational in nature. This study adds to the limited number of polyclonal sera-based studies on Rabies nucleoprotein.
Pages: 516-519  |  172 Views  83 Downloads


The Pharma Innovation Journal
How to cite this article:
Hridya Susan Varughese, Chethana Chandrahasa, Kavitha GM, Akhila DS, Shreya Gopinath, Kavitha Govindaiah, Tilak Chandan, Vinay C Prakash Rao, Madhusudhan Hosamani, Sharada Ramakrishnaiah, Rathnamma Doddamane, Divakar Hemadri, Shrikrishna Isloor. Development of recombinant partial nucleoprotein of rabies virus as the potential antigen for developing in house immunodiagnostics. Pharma Innovation 2023;12(1):516-519.

Call for book chapter